| Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now? |
HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance. |
zacks.com |
2025-05-16 15:26:04 |
Czytaj oryginał (ang.) |
| Buy Amazon (AMZN), Shopify (SHOP) and Hims & Hers (HIMS) in May And Hold Forever |
There's a well-known saying in the investing world, which advises investors to “sell in May and go away. |
247wallst.com |
2025-05-16 15:03:05 |
Czytaj oryginał (ang.) |
| Bet on Winning DuPont Analysis & Pick 3 Top Stocks |
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM). |
zacks.com |
2025-05-16 11:21:15 |
Czytaj oryginał (ang.) |
| Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade) |
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though reliance on GLP-1 drugs and competition are key risks. |
seekingalpha.com |
2025-05-16 09:00:16 |
Czytaj oryginał (ang.) |
| Hims & Hers Health, Inc. (HIMS) is a Great Momentum Stock: Should You Buy? |
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-05-14 17:01:14 |
Czytaj oryginał (ang.) |
| Top Health & Fitness Stocks to Buy for the Wellness Boom |
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit. |
zacks.com |
2025-05-14 14:01:25 |
Czytaj oryginał (ang.) |
| Hims & Hers stock price nears crucial level: is it a buy or sell? |
Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue in the coming years. HIMS shares surged by almost 16% on Tuesday, reaching its highest level since February. |
invezz.com |
2025-05-14 06:14:00 |
Czytaj oryginał (ang.) |
| Cautious? Risky? Our Volatility Scorecard Can Help |
Subscribers to Chart of the Week received this commentary on Sunday, May 11. |
schaeffersresearch.com |
2025-05-13 15:08:35 |
Czytaj oryginał (ang.) |
| Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight |
Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030 guidance suggests a $64 fair value per share, with potential to far exceed that price due to management's conservative guidance. I think HIMS stock's fair value is above $84 per share, with potential to upwards of $300 per share in a bullish case scenario (2030 DCF model). |
seekingalpha.com |
2025-05-12 15:15:31 |
Czytaj oryginał (ang.) |
| Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns |
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX. |
zacks.com |
2025-05-12 14:10:52 |
Czytaj oryginał (ang.) |
| Hims & Hers: Still Undervalued For These 2 Reasons |
Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.' |
seekingalpha.com |
2025-05-12 13:04:45 |
Czytaj oryginał (ang.) |
| Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth |
Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue decline due to product transitions, management reaffirmed full-year 2025 revenue guidance of $2.3–2.4B and raised adj. EBITDA guidance to $295–335M. Long-term growth prospects remain strong, with a target of $6.5B+ revenue and $1.3B+ adj. EBITDA by 2030, driven by TAM penetration, new specialties, and AI integration. |
seekingalpha.com |
2025-05-12 12:30:00 |
Czytaj oryginał (ang.) |
| Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30% |
Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% YoY revenue growth and a 345% increase in net income, highlighting a sustainable and resilient business model. The company's personalized healthcare approach and new product launches, like low testosterone and menopause support, are driving subscriber growth and higher revenue per subscriber. |
seekingalpha.com |
2025-05-12 06:40:48 |
Czytaj oryginał (ang.) |
| Massive Hims & Hers News: $1 Billion on AI and Acquisitions |
Hims & Hers (NYSE: HIMS) stock has been on fire in 2025, and the company just got more great news after upsizing a $450 million convertible debt offering to up to $1 billion. The growth of Hims & Hers should move overseas, and artificial intelligence will play a bigger role in its future now. |
fool.com |
2025-05-10 10:01:00 |
Czytaj oryginał (ang.) |
| Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? |
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-05-09 14:06:10 |
Czytaj oryginał (ang.) |
| Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare |
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of. |
businesswire.com |
2025-05-09 02:25:00 |
Czytaj oryginał (ang.) |
| Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started |
If short sellers were hoping for a flop from Hims & Hers Health Inc. HIMS, they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after the bell on Monday, and instead of the crash shorts were counting on, the market got a bullish cocktail: strong guidance, solid revenue growth and a headline-making partnership with Novo Nordisk A/S NVO. |
benzinga.com |
2025-05-08 19:00:26 |
Czytaj oryginał (ang.) |
| Hims & Hers: The Road To Blue Chip Status |
Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS' best quarter to date. The markets need to put some respect on Andrew Dudum and his world-class team. |
seekingalpha.com |
2025-05-08 13:45:01 |
Czytaj oryginał (ang.) |
| Hims & Hers Soars Again--Explosive Growth Meets Lofty Expectations |
Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo Nordisk partnership. Despite trading at a high valuation, technical indicators suggest continued short-term momentum, with potential for a pullback near February highs. The company's evolution from a telehealth startup to a health-tech giant showcases its strong growth, profitability, and expanding service offerings. |
seekingalpha.com |
2025-05-08 11:57:36 |
Czytaj oryginał (ang.) |
| Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare |
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant. |
businesswire.com |
2025-05-08 11:57:00 |
Czytaj oryginał (ang.) |
| Hims & Hers: Shortage-Driven Sell-Off Appears Overdone; Buy |
Hims and Hers' stock dropped 25% due to the end of the semaglutide shortage, but the sell-off is seen as exaggerated. Despite the setback, Hims and Hers continue to show strong subscriber growth and profitability, with a 269.49% increase since December 2021. The company benefits from political support and a $5 billion market cap boost post-Super Bowl, indicating potential for explosive growth. |
seekingalpha.com |
2025-02-27 08:39:30 |
Czytaj oryginał (ang.) |
| Why Hims & Hers Stock Rebounded on Wednesday |
Hims & Hers (HIMS 5.09%) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the week. Several analysts raised their price targets on the specialty healthcare company on that slump, which helped Hims & Hers recover by more than 5% in mid-week action. |
fool.com |
2025-02-26 21:15:36 |
Czytaj oryginał (ang.) |
| Hims & Hers: Down 45% In 5 Days, Is The Stock Still A Buy? |
Hims & Hers Health is a promising disruptor in the $4T US healthcare market, aiming to become the most trusted health & wellness brand. Despite recent stock volatility, Hims & Hers' Q4 2024 report showed strong growth, with revenues up 95% y/y and robust 2025 guidance. The end of semaglutide compounding poses challenges, but Hims & Hers is expected to maintain growth through diversified offerings and new specialties. |
seekingalpha.com |
2025-02-26 12:02:20 |
Czytaj oryginał (ang.) |
| Wall Street's Most Wanted: 2 Highly Shorted Stocks Right Now |
Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling shares short are hoping that the price of certain stocks falls so that they can make a profit. |
marketbeat.com |
2025-02-26 10:45:03 |
Czytaj oryginał (ang.) |
| Hims & Hers Health: Focus On The Future, Not GLP-1s |
Hims & Hers Health, Inc. reported strong growth, with Q4 sales up $80 million sequentially, yet HIMS stock fell due to GLP-1 business confusion. The online health and wellness platform guided to $2.3 billion in 2025 revenues and $300 million in adjusted EBITDA despite the FDA ending GLP-1 shortages. Hims' non-GLP-1 sales grew 43% to $1.2 billion, showing its business isn't reliant on GLP-1 sales. |
seekingalpha.com |
2025-02-25 16:22:06 |
Czytaj oryginał (ang.) |
| HIMS Stock Craters – Is It a Buying Opportunity? |
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn't guarantee it would be able to continue selling its knockoff versions of weight-loss drugs Ozempic and Wegovy. |
247wallst.com |
2025-02-25 14:41:36 |
Czytaj oryginał (ang.) |
| HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts |
Hims & Hers' revenue channels witness strong growth on the back of solid product demand in the fourth quarter. |
zacks.com |
2025-02-25 14:10:50 |
Czytaj oryginał (ang.) |
| Hims Stock Crashed After Earnings. What Went Wrong? |
In this video, I will go over the fourth-quarter earnings report from Hims & Hers (HIMS -27.60%) and explain why the stock crashed on Tuesday. Watch the short video to learn more, consider subscribing, and click the special offer link below. |
fool.com |
2025-02-25 13:51:27 |
Czytaj oryginał (ang.) |
| Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know |
Hims & Hers (HIMS -27.66%) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are concerned about the future of GLP-1s. |
fool.com |
2025-02-25 13:45:01 |
Czytaj oryginał (ang.) |
| Hims & Hers shares plunge 28% on concerns over weight loss business, margins |
Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same period last year. |
cnbc.com |
2025-02-25 12:56:56 |
Czytaj oryginał (ang.) |
| Hims & Hers CFO talks Q4 earnings |
Hims & Hers Health (HIMS) stock is dropping in extended hours upon the telehealth company's fourth quarter earnings release, topping revenue ($481.14 million vs. forecasts of $470.39 million) and total subscribers estimates (2.23 million vs. |
youtube.com |
2025-02-25 12:52:26 |
Czytaj oryginał (ang.) |
| Bitcoin Concerns, SPX Upside to "$6030" & HIMS Sinks |
As Bitcoin (/BTC) falls to 3-month lows, Kevin Green points to fundamental factors that are weighing on its price activity. He says the technical setup indicates possible selling pressure remains for popular crypto asset. |
youtube.com |
2025-02-25 10:54:40 |
Czytaj oryginał (ang.) |
| Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long. |
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer. |
marketwatch.com |
2025-02-25 09:29:00 |
Czytaj oryginał (ang.) |
| Hims & Hers shares drop on doubts over weight-loss business forecast |
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight-loss drugs. |
reuters.com |
2025-02-25 09:21:28 |
Czytaj oryginał (ang.) |
| Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade) |
I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024, with a broader weight loss strategy including oral treatments and liraglutide. I believe affordability will drive demand for Hims' weight loss products, as many overweight Americans may struggle to afford Novo Nordisk's expensive GLP-1 treatments. |
seekingalpha.com |
2025-02-25 08:47:01 |
Czytaj oryginał (ang.) |
| Hims & Hers Earnings: Very Strong Business, In A Very Crowded Trade |
Hims & Hers experienced a sell-off due to profit-taking and weaker-than-expected EBITDA margins, despite strong revenue growth. The company is projected to generate over $2 billion in revenues and $350 million in free cash flow in 2025, with no debt. While EBITDA margins have fluctuated, free cash flow remains strong, making the stock attractive at 26x forward free cash flow. |
seekingalpha.com |
2025-02-25 06:20:14 |
Czytaj oryginał (ang.) |
| Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity |
Hims & Hers stock fell ~19% post-Q4 earnings despite revenue beating expectations and EPS aligning with estimates, attributed to gross margin concerns and potential dependency on GLP-1 for future growth. The company's growth remains strong, with a 95% YoY revenue increase, an expanding subscriber base, and higher revenue per subscriber, indicating robust market capture and customer loyalty. Future potential is promising with new service additions, a vast addressable market, and strategic diversification, mitigating risks from competition and regulatory changes. |
seekingalpha.com |
2025-02-25 06:01:51 |
Czytaj oryginał (ang.) |
| Hims & Hers CFO, drone regulation: Asking for a Trend |
Josh Lipton takes a closer look at the top stories investors need to know after the closing bell on Asking for a Trend. Hims & Hers Health (HIMS) CFO Yemi Okupe breaks down the quarterly results as shares plunge following the report. |
youtube.com |
2025-02-25 00:49:54 |
Czytaj oryginał (ang.) |
| Hims & Hers: Post Earnings Drop Is Very Welcomed |
Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted EBITDA increased 163% YoY, highlighting long-term growth potential. Management's goal of 10 million subscribers in 5–6 years, with AI integration and Trybe Labs acquisition, presents a bullish opportunity. |
seekingalpha.com |
2025-02-24 23:54:43 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-24 21:31:13 |
Czytaj oryginał (ang.) |
| Hims & Hers: Ready For Liftoff In 2025 |
Despite a recent 30% stock drawdown, Hims & Hers Health, Inc. remains a “Strong Buy” due to its undervaluation and long-term growth potential in the healthcare tech market. Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its strong growth trajectory. Management's raised FY-2024 revenue outlook and strategic initiatives, including new weight loss offerings and personalization, bolster confidence in sustained growth. |
seekingalpha.com |
2025-01-02 10:30:00 |
Czytaj oryginał (ang.) |
| Is Hims & Hers Health a Millionaire Maker? |
Hot telehealth stock Hims & Hers Health (HIMS -3.93%) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high. |
fool.com |
2025-01-01 07:56:00 |
Czytaj oryginał (ang.) |
| 3 Hot Stocks That Can Double Again in 2025 |
Some of the hottest stocks of 2024 may surprise you. A few more than 100 stocks with market caps north of $2 billion doubled over the past year. |
fool.com |
2024-12-31 13:45:00 |
Czytaj oryginał (ang.) |
| Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-12-27 12:06:25 |
Czytaj oryginał (ang.) |
| 4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run |
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains. |
zacks.com |
2024-12-23 13:56:10 |
Czytaj oryginał (ang.) |
| Hims & Hers: Still Trading At A Massive Discount |
Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and differentiation. HIMS' financials are robust, with 40% annual subscription growth and a forecasted 60%+ revenue growth for 2024, indicating significant undervaluation despite a 200% YTD increase. The company is expanding its product offerings and leveraging AI through MedMatch, enhancing treatment consistency and customer satisfaction, further solidifying its market position. |
seekingalpha.com |
2024-12-23 08:23:39 |
Czytaj oryginał (ang.) |
| Will the falling Hims & Hers stock price recover in 2025? |
Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in the industry like CVS Health and Walgreens Boots Alliance and CVS Health, plunged. |
invezz.com |
2024-12-22 05:01:19 |
Czytaj oryginał (ang.) |
| Hims & Hers Stock: Growth, Noise, and Where to Focus Now |
Hims & Hers Health (HIMS -7.67%) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in this video. |
fool.com |
2024-12-20 08:00:00 |
Czytaj oryginał (ang.) |
| Hims and Hers Health Stock Testing Key Trendline |
Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. |
schaeffersresearch.com |
2024-12-19 17:39:33 |
Czytaj oryginał (ang.) |
| CEO of HIMS dumps over $6 million of stock |
Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven't exactly been performing well as of late. |
finbold.com |
2024-12-18 11:05:02 |
Czytaj oryginał (ang.) |
| Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-12-16 12:01:17 |
Czytaj oryginał (ang.) |
| HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further? |
Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust growth in 2024. Shares of the company have risen 43% in the past month, significantly outperforming the industry's growth of 5.5%. |
zacks.com |
2024-12-16 10:31:16 |
Czytaj oryginał (ang.) |
| The Shape of America 2024: Hims & Hers Shares an In-Depth Look Into How Americans Feel About Weight |
SAN FRANCISCO--(BUSINESS WIRE)--For most Americans, weight is more than just a number. It shapes our health, our mood, our confidence, our spending, and the decisions we make in our day to day lives. In fact, 75% of us think about our weight every single day, and 14% say it's constantly on our minds. At Hims & Hers (NYSE: HIMS), we know that health is personal, which is why we focus on making high-quality, affordable personalized health and wellness solutions to our customers. Along with pr. |
businesswire.com |
2024-12-12 11:00:00 |
Czytaj oryginał (ang.) |
| Hims & Hers: Look At What Matters Most |
Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS companies in terms of scalability and growth potential. The company reported stellar Q3 FY2024 results with a 77% YoY revenue increase, driven by strong subscriber growth and high retention rates in personal health services. Despite regulatory risks and competition, HIMS' advanced tech platform and focus on personalized healthcare provide a strong foundation for long-term shareholder value. |
seekingalpha.com |
2024-12-12 06:51:09 |
Czytaj oryginał (ang.) |
| 4 Stocks That Crushed Analyst Estimates by More Than Double |
Every earnings season has its share of winners and losers, as well as top and bottom-line surprises and disappointments. This recent earnings season is no different. |
marketbeat.com |
2024-12-11 09:01:29 |
Czytaj oryginał (ang.) |
| Options Action: Bearish bets on Hims |
Mike Khouw joins 'Fast Money' to talk the options trade around Hims. |
youtube.com |
2024-12-10 20:50:50 |
Czytaj oryginał (ang.) |
| Market Navigator: Hims & Hers Health up 250% in 2024 |
Todd Gordon, founder of Inside Edge Capital, joins CNBC's 'Power Lunch' to discuss why he's keeping an eye on shares of these healthcare picks, potential headwinds, and more. |
youtube.com |
2024-12-10 17:23:24 |
Czytaj oryginał (ang.) |
| Hims & Hers: The Show Must Go On |
Hims & Hers Health stock is substantially undervalued despite a massive YTD rally, presenting a strong buy opportunity due to a myriad of catalysts. The company demonstrates exponential revenue growth, improving operating margins, and successful customer acquisition cost reduction, driven by personalized solutions and innovative product formats. HIMS is financially strong with minimal debt and a dominant market share, strategically positioned to leverage AI-driven tools and proprietary systems for growth. |
seekingalpha.com |
2024-12-05 11:30:00 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's November 2024 New Analysts |
Twenty-six new analysts joined Seeking Alpha in November, sharing diverse investment ideas highlighting their unique backgrounds and expertise. Top picks include U.S. Bancorp Preferred Series A, Hershey, and PepsiCo, emphasizing undervalued opportunities, dividend stability, and strategic growth potential. Analysts also spotlighted strong sell recommendations like BlackRock Science and Technology Trust and Luckin Coffee, citing fundamental flaws and competitive disadvantages. |
seekingalpha.com |
2024-12-05 10:30:00 |
Czytaj oryginał (ang.) |
| 2 Telehealth Stocks That Could Gain from Trump's New FDA Pick |
The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University in Baltimore, Maryland, and also serves as the chief medical officer at Sesame, an online telehealth platform. |
marketbeat.com |
2024-12-05 10:15:10 |
Czytaj oryginał (ang.) |